HUMAN-BREAST CANCER - CORRELATION OF RELAPSE AND SURVIVAL WITH AMPLIFICATION OF THE HER-2 NEU ONCOGENE
HUMAN-BREAST CANCER - CORRELATION OF RELAPSE AND SURVIVAL WITH AMPLIFICATION OF THE HER-2 NEU ONCOGENE
复制标题
DOI：
10.1126/science.3798106
复制
发表时间：
1987-01-09
期刊：
影响因子：
56.9
通讯作者：
MCGUIRE, WL
中科院分区：
文献类型：
--
作者：
SLAMON, DJ;CLARK, GM;MCGUIRE, WL
HER-2/neuoconcogene是erbB样癌基因家族的一员，与表皮生长因子受体相关，但不同。该基因已被证明在人类乳腺癌细胞系中扩增。在目前的研究中，研究了189例原发性人类乳腺癌中该基因的改变。HER-2/neu在30%的肿瘤中扩增2- 20倍以上。基因扩增与几个疾病参数的相关性进行了评估。HER-2/neugene扩增是乳腺癌患者总生存期和复发时间的重要预测因子。即使对其他已知的预后因素进行调整，它仍然保持其重要性。此外，HER-2/neuamplification在淋巴结阳性疾病中的预后价值高于目前使用的大多数预后因素，包括乳腺癌受体状态。这些数据表明，该基因可能在人类乳腺癌的生物学行为和/或发病机制中发挥作用。
The HER-2/neuoncogene is a member of theerbB-like oncogene family, and is related to, but distinct from, the epidermal growth factor receptor. This gene has been shown to be amplified in human breast cancer cell lines. In the current study, alterations of the gene in 189 primary human breast cancers were investigated. HER-2/neuwas found to be amplified from 2- to greater than 20-fold in 30% of the tumors. Correlation of gene amplification with several disease parameters was evaluated. Amplification of the HER-2/neugene was a significant predictor of both overall survival and time to relapse in patients with breast cancer. It retained its significance even when adjustments were made for other known prognostic factors. Moreover, HER-2/neuamplification had greater prognostic value than most currently used prognostic factors, including hormonal-receptor status, in lymph node-positive disease. These data indicate that this gene may play a role in the biologic behavior and/or pathogenesis of human breast cancer.